Market Place
Sourcing Support
FDA`s Accelerated Approval Drives Momentum for Fatal Diseases
02 Dec 2024 //
BIOSPACE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Sarepta axes late-phase DMD drug over safety signal
08 Nov 2024 //
FIERCE BIOTECH
Sarepta`s Elevidys blows sales expectations out of the water
07 Nov 2024 //
FIERCE PHARMA
Sarepta Therapeutics Announces Q3 2024 Results & Developments
06 Nov 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule
31 Oct 2024 //
BUSINESSWIRE
Sarepta Therapeutics Q3 2024 Financial Results Announcement
23 Oct 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Rule
30 Sep 2024 //
BUSINESSWIRE
Sarepta To Present At World Muscle Society Congress
26 Sep 2024 //
BUSINESSWIRE
Sarepta Appoints Deirdre Connelly To Board
16 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces 2024-25 Route 79 Duchenne Scholarship Recipients
05 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rules
30 Aug 2024 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q2 2024 Results And Corporate Developments
07 Aug 2024 //
BUSINESSWIRE
Sarepta Faces Lower Revenue For Duchenne Gene Therapy
07 Aug 2024 //
ENDPTS
Sarepta Therapeutics Announces Inducement Grants
31 Jul 2024 //
BUSINESSWIRE
Sanofi sues Sarepta, claiming Duchenne gene therapy Elevidys infringes 2 manufacturing patents
31 Jul 2024 //
FIERCE PHARMA
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
29 Jul 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
28 Jun 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
28 Jun 2024 //
BUSINESSWIRE
US FDA approves expanded use of Sarepta`s Duchenne gene therapy; shares jump
21 Jun 2024 //
REUTERS
Great Point Partners acquires German CDMO Lyocontract
13 Jun 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Per Nasdaq Rule
31 May 2024 //
BUSINESSWIRE
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
08 May 2024 //
BIOSPACE
Sarepta Therapeutics executive sells $508,900 in stock
07 May 2024 //
INVESTING
Gene Therapy Pioneer Mendell Named To TIME100 Health List
03 May 2024 //
BUSINESSWIRE
ICER pushes back on FDA`s potential of Sarepta`s gene therapy to full approval
02 May 2024 //
ENDPTS
Sarepta Q1 2024 Results, Recent Corporate Developments
01 May 2024 //
BUSINESSWIRE
FDA decision on Sarepta’s Duchenne gene therapy could come earlier than expected
01 May 2024 //
ENDPTS
Sarepta Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)
30 Apr 2024 //
BUSINESSWIRE
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
24 Apr 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Mar 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
19 Mar 2024 //
PRESS RELEASE
US spent $3B on DMD treatments
12 Mar 2024 //
ENDPTS
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04 Mar 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Feb 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79
29 Feb 2024 //
PRESS RELEASE
Elevidys gains steam amid Sarepta`s efforts to widen FDA label
29 Feb 2024 //
FIERCE PHARMA
Sarepta Announces Fourth Quarter and Full-Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Internal documents shed new light on Sarepta FDA decision
27 Feb 2024 //
ENDPTS
Sarepta to Announce Fourth Quarter and Full-Year 2023 Financial Results
21 Feb 2024 //
BUSINESSWIRE
Sarepta`s Elevidys expansion bid gets fast review without adcomm
16 Feb 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2024 //
BUSINESSWIRE
Sarepta Announces Positive Data from Part B of MOMENTUM, a Phase 2 of SRP-5051
29 Jan 2024 //
BUSINESSWIRE
Sarepta Announces Positive Data from Phase 2 Study of SRP-5051
29 Jan 2024 //
PRESS RELEASE
Sarepta Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003
16 Jan 2024 //
BUSINESSWIRE
Sarepta Therapeutics Initiates Screening in Phase 3 Study of SRP-9003
16 Jan 2024 //
PRESS RELEASE
FDA`s CBER chief hints at expanding Sarepta`s gene therapy label
10 Jan 2024 //
ENDPTS
Sarepta Reports Preliminary* Fourth Quarter & Full-Year 2023 Net Product Revenue
08 Jan 2024 //
BUSINESSWIRE
Sarepta to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Dec 2023 //
BUSINESSWIRE
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label
22 Dec 2023 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Nov 2023 //
PRESS RELEASE
Is Sarepta Therapeutics Stock a Bad-News Buy?
09 Nov 2023 //
FOOL
Sarepta Therapeutics to Present at the UBS Biopharma Conference
02 Nov 2023 //
BUSINESSWIRE
Sarepta`s Elevidys off to strong start despite label restriction
02 Nov 2023 //
FIERCE PHARMA
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Oct 2023 //
BUSINESSWIRE
Catalent`s stock down after Sarepta’s PhIII Duchenne study misses endpoint
31 Oct 2023 //
ENDPTS
Sarepta slumps as muscle disorder trial data signals `uphill battle`
31 Oct 2023 //
REUTERS
